Millipore Sigma Vibrant Logo

567809 Src Inhibitor, PP1 - CAS 172889-26-8 - Calbiochem

The Src Inhibitor PP1, also referenced under CAS 172889-26-8, controls the biological activity of Src. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo-d-3,4-pyrimidine

View Products on Sigmaaldrich.com
567809
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
172889-26-8C₁₆H₁₉N₅

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
567809-1MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Glasflasche 1 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewA cell-permeable pyrazolopyrimidine compound that is shown to inhibit Src family tyrosine kinases Lck, Fyn, Hck, and Src (IC50 = 5, 6, 20, and 170 nM, respectively), as well as non-Src family kinases such as CSK, RIP2, and CK1δ (IC50 = 640 nM, 26 nM, 170 nM, respectively), in in vitro kinase assays. At 1 µM, in vitro kinase activity is reduced by more than 57% for p38α, p38β, CK1δ, CSK, RIP2, and GAK, while exhibiting much lower activity against more than 60 other kinases. Kinetic studies employing Src and [poly Glu-Tyr 4:1] indicate that the inhibition is mixed competitive with respect to the substrate and non-competitive with respect to ATP. PP1 also demonstrates anti-growth properties in several B lymphoma cultures of human and murine origins (IC50 = 2.5 to 8.0 µM) and pediatric brain tumor cells (IC50 = 1.1 to 9.7 µM). Also available in InSolution™ format (Cat. No. 539741).
      Catalogue Number567809
      Brand Family Calbiochem®
      Synonyms4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo-d-3,4-pyrimidine
      References
      ReferencesKe, J., et.al. 2009. Mol. Cancer 8, 132.
      Sikkema, A.H., et al. 2009. Cancer Res. 69, 5987.
      Bain, J., et al. 2007. Biochem. J. 408, 297.
      Bain, J., et al. 2003. Biochem. J. 371, 199.
      Karni, R., et al. 2003. FEBS Lett. 537, 47.
      Hanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.
      Product Information
      CAS number172889-26-8
      FormOff-white solid
      Hill FormulaC₁₆H₁₉N₅
      Chemical formulaC₁₆H₁₉N₅
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      567809-1MG 04055977190373

      Documentation

      Src Inhibitor, PP1 - CAS 172889-26-8 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      Src Inhibitor, PP1 - CAS 172889-26-8 - Calbiochem Analysenzertifikate

      TitelChargennummer
      567809

      Literatur

      Übersicht
      Ke, J., et.al. 2009. Mol. Cancer 8, 132.
      Sikkema, A.H., et al. 2009. Cancer Res. 69, 5987.
      Bain, J., et al. 2007. Biochem. J. 408, 297.
      Bain, J., et al. 2003. Biochem. J. 371, 199.
      Karni, R., et al. 2003. FEBS Lett. 537, 47.
      Hanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-April-2015 JSW
      Synonyms4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo-d-3,4-pyrimidine
      DescriptionA cell-permeable pyrazolopyrimidine compound that is shown to inhibit Src family tyrosine kinases Lck, Fyn, Hck, and Src (IC50 = 5, 6, 20, and 170 nM, respectively), as well as non-Src family kinases such as CSK, RIP2, and CK1δ (IC50 = 640 nM, 26 nM, 170 nM, respectively), in in vitro kinase assays. At 1 µM, in vitro kinase activity is reduced by more than 57% for p38α, p38β, CK1δ, CSK, RIP2, and GAK, while exhibiting much lower activity against more than 60 other kinases. Kinetic studies employing Src and [poly Glu-Tyr 4:1] indicate that the inhibition is mixed competitive with respect to the substrate and non-competitive with respect to ATP. PP1 also demonstrates anti-growth properties in several B lymphoma cultures of human and murine origins (IC50 = 2.5 to 8.0 µM) and pediatric brain tumor cells (IC50 = 1.1 to 9.7 µM). Also available in InSolution™ format (Cat. No. 539741.
      FormOff-white solid
      CAS number172889-26-8
      Chemical formulaC₁₆H₁₉N₅
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (25 mg/ml)
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesKe, J., et.al. 2009. Mol. Cancer 8, 132.
      Sikkema, A.H., et al. 2009. Cancer Res. 69, 5987.
      Bain, J., et al. 2007. Biochem. J. 408, 297.
      Bain, J., et al. 2003. Biochem. J. 371, 199.
      Karni, R., et al. 2003. FEBS Lett. 537, 47.
      Hanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.